Strides Pharma inks deal with Arrow Pharma to sell Australian business
Category: #health  By Mateen Dalal  Date: 2019-07-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Strides Pharma inks deal with Arrow Pharma to sell Australian business

It had earlier informed it will withdraw its investment in Arrow Pharmaceuticals for an agreed price of AUD 394 million

Reports confirm that Strides Pharma Science, a Bangalore based pharmaceutical company, has recently announced that its subsidiary has signed the agreements for sale of its overall Australian business to Arrow Pharmaceuticals upon receipt of all necessary approvals.

According to Strides Pharma Science, the company has received all necessary approvals and Strides Pharma Global, a step-down subsidiary of the company in Singapore, has officially signed the definitive agreements for the transaction.

Apparently, earlier in the year, Strides Pharma Science had formally decided to withdraw its investment in Arrow Pharmaceuticals for an agreed price of AUD 394 million.

Sources mentioned that the company is expecting the transaction to close on or around July 10, 2019. SPG will receive AUD 300 million instantly at closing and remaining AUD 94 million will be received as a deferred consideration that would be backed by a secure interest-bearing instrument.

Striders Pharma shares were trading at INR 406.50 a share, up by 1.92 percent, on the BSE at the time.

Recently, the US Food and Drug Administration has reportedly issued a warning letter to Strides Pharma Science for its facility in Puducherry, India. However, the drug firm did not provide any kind of details of the contents of the warning letter received from the official regulator.

The company mentioned that its Puducherry site presently manufactures six products which will not get affected by the existing development.

According to company sources, the 10 abbreviated new drug applications (ANDAs) which are currently pending approval from the Puducherry facility will get postponed till the site is reclassified. Striders pharma insists that it maintains its growth guidance for the US market.

Sources further added that the company is determined to comply with the highest standards of quality and adherence and will work in collaboration with the USFDA to settle all issues addressed in the warning letter.

Source Credits: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-pharma-arm-signs-pacts-for-sale-of-australian-business-to-arrow-pharma/articleshow/70020119.cms

https://www.business-standard.com/article/pti-stories/strides-pharma-puducherry-unit-receives-warning-letter-from-usfda-119070200365_1.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...